India Britain France city Sanofi vaccine patient India Britain France city Sanofi

India approves late-stage trial for Glaxo-Sanofi Covid vaccine

Reading now: 244
www.livemint.com

vaccine candidate, reported news agency Reuters. France's Sanofi and Britain's GSK in May kicked off global trials to include more than 35,000 adults to test the dose.

They hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response, the report added.

The Indian arm of the studies will enroll nearly 3,000 adults between the ages of 18 years and 55 years, as per India's clinical trial registry.

The assessment is expected to run for a year and the first enrolment in India is shown to have been made on Tuesday. "As the virus continues to evolve, we are anticipating what will be needed in the coming months and years, and accordingly, have adapted our vaccine development program,"

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA